Determining glioma response to radiation therapy using recombinant peptides

Expert Review of Anticancer Therapy

Volumn 8, Issue 11, 2008, Pages 1787-1796

  Diaz, Roberto ^a   Passarella, Ralph J ^a   Hallahan, Dennis E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biomarker; Glioma; Imaging; Phage display; Radiation; Recombinant peptide

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BEVACIZUMAB; CISPLATIN; CONTRAST MEDIUM; FIREFLY LUCIFERASE; INTEGRIN; LIPOCORTIN 5; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; RADIOSENSITIZING AGENT; RECOMBINANT PROTEIN; SEMAXANIB; SUNITINIB; TAXANE DERIVATIVE; TECHNETIUM 99M; TEMOZOLOMIDE; TRACER; TUMOR MARKER; VASCULOTROPIN INHIBITOR; VATALANIB;

BINDING AFFINITY; BIOLUMINESCENCE; BIOPANNING; CANCER RADIOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FLUORESCENCE; GENE EXPRESSION; GLIOMA; GLIOSARCOMA; HUMAN; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MICROVASCULATURE; MOLECULAR IMAGING; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHAGE DISPLAY; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RADIOSENSITIVITY; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; BRAIN NEOPLASMS; GLIOMA; HUMANS; PEPTIDES; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 60849116190     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.11.1787     Document Type: Review

References (92)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
2. Carpentier AF. Neuro-oncology: the growing role of chemotherapy in glioma. Lancet Neurol. 4(1), 4-5 (2005).
3. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973-1991. J. Neurosurg. 88(1), 1-10 (1998).
4. Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin. Oncol. 310), 635-644 (2004).
5. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005).
6. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat. Rev. Drug Discov. 7(7), 591-607 (2008).
7. Pichler BJ, Wehrl HF, Judenhofer MS. Latest advances in molecular imaging instrumentation. J. Nucl. Med. 49(Suppl. 2), 5S-23S (2008).
8. Mankoff DA. A definition of molecular imaging. J. Nucl. Med. 48(6), 18N-21N (2007).
9. Dinca EB, Sarkaria JN, Schroeder MA et al. Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. J. Neurosurg. 107(3), 610-616 (2007).
10. Lamfers ML, Fulci G, Gianni D et al. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovifus in glioma-bearing mice monitored by bioluminescence imaging. Mol. Ther. 14(6), 779-788 (2006).
11. Montet X, Ntziachristos V, Grimm J, Weissleder R. Tomographic fluorescence mapping of tumor targets. Cancer Res. 65(14), 6330-6336 (2005).
12. Hsu AR, Cai W, Veeravagu A et al. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J. Nucl. Med. 48(3), 445-454 (2007).
13. Rehemtulla A, Hall DE, Stegman LD et al. Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy. Mol. Imaging 1(1), 43-55 (2002).
14. Chenevert TL, Stegman LD, Taylor JM et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J. Natl Cancer Inst. 92(24), 2029-2036 (2000).
15. Lee KC, Hamstra DA, Bhojani MS, Khan AR Ross BD, Rehemtulla A. Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. Clin. Cancer Res. 13(6), 1839-1846 (2007).
16. Moffat BA, Chenevert TL, Meyer CR et al. The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Aeoplasia 8 (4), 259-267 (2006).
17. Tofts Ps, Brix G, Buckley DL et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J. Magn. Reson. Imaging 100), 223-232 (1999).
18. Yankeelov TE, DeBusk LM, Billheimer DD et al. Repeatability of a reference region model for analysis of murine DCE-MRI data at 7T. J. Magn. Reson. Imaging 24(5), 1140-1147 (2006).
19. Yankeelov TE, Luci JJ, Lepage M et al. Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magn. Reson. Imaging 23 (4), 519-529 (2005).
20. Morgan B, Thomas AL, Drevs J et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two Phase I studies. J. Clin. Oncol. 21(21), 3955-3964 (2003).
21. Mardor Y, Pfeffer R, Spiegelmann R et al. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high β-value diffasion-weighted magnetic resonance imaging. J. Clin. Oncol. 21(6), 1094-1100 (2003).
22. Mardor Y, Roth Y, Ochershvilli A et al. Pretreatment prediction of brain tumors' response to radiation therapy using high β-value diffusion-weighted MRI. Neoplasia 6(2), 136-142 (2004).
23. Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (1), 83-95 (2007).
24. Aina OH, Marik J, Liu R, Lau DH, Lam KS. Identification of novel targeting peptides for human ovarian cancer cells using 'one-bead one-compound' combinatorial libraries. Mol. Cancer Ther. 4(5), 806-813 (2005).
25. Krumpe LRH, Mori T. The use of phage-displayed peptide libraries to develop tumor-targeting drugs. Int. J. Peptide Res. Therapeut. 120), 79-91 (2006).
26. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc. Natl Acad. Sci. USA 101 (51), 17867-17872 (2004).
27. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31(1), 1-9 (1998).
28. Kolodgie FD, Petrov A, Virmani R et al. Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V. a technique with potential for noninvasive imaging of vulnerable plaque. Circulation 108(25), 3134-3139 (2003).
29. Narula J, Acio ER, Narula N et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat. Med. 7(12), 1347-1352 (2001).
30. van de Wiele C, Lahorte C, Vermeersch H et al. Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tornography. J. Clin. Oncol. 21(18), 3483-3487 (2003).
31. Bethocine T, Steinmetz N, Hustinx R et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin. Cancer Res. 8 (9), 2766-2774 (2002).
32. Lahorte CM, van de Wiele C, Bacher K et al. Biodistribution and dosimetry study of 123I-rh-annexin V in mice and humans. Nucl. Med. Comm. 24 (8), 871-880 (2003).
33. Aina OH, Sroka TC, Chen ML, Lam KS. Therapeutic cancer targeting peptides. Biopolymers 66(3), 184-199 (2002).
34. Nilsson F, Tarli L, Viti F, Neri D. Theuse of phage display for the development of tumour targeting agents. Adv. Drug Deliv. Rev. 43(2-3), 165-196 (2060).
35. Ladner RC. Polypeptides from phage display. A superior source of in vivo imaging agents. Q J. Nucl. Med. 43(2), 119-124 (1999).
36. Liu B, Huang L, Sihlbom C, Burlingame A, Marks JD. Towards proteome-wide production of monoclonal antibody by phage display. J. Mol. Biol. 315 (5), 1063-1073 (2002).
37. Rusckowski M, Qu T, Pullman J et al. Inflammation and infection imaging with a 99mTc-neutrophil elastase inhibitor in monkeys. J. Nucl. Med. 41(2,), 363-374 (2000).
38. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med. 49 (Suppl. 2), 113S-128S (2008),
39. Hallahan DE, Staba-Hogan MJ, Virudachalam S, Kolchinsky A. X-ray-induced P-selectin localization to the lumen of tumor blood vessels. Cancer Res. 58(22), 5216-5220 (1998).
40. Hallahan D, Clark ET, Kuchibhotla J, Gewertz BL, Collins T. E-selectin gene induction by ionizing radiation is independent of cytokine induction. Biochem. Biophys. Res. Commun. 217(3), 784-795 (1995).
41. Hallahan D, Kuchibhotla J, Wyble C. Cell adhesion molecules mcdiate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res. 56(22), 5150-5155 (1996).
42. Hallahan DE, Virudachalam S. Ionizing radiation mediates expression of cell adhesion molecules in distinct histological patterns within the lung. Cancer Res. 57(11), 2096-2099 (1997).
43. Hallahan DE, Virudachalam S. Intercellular adhesion molecule 1 knockout abrogates radiation induced pulmonary inflammation. Proc. Natl Acad. Sci. USA 94(12), 6432-6437 (1997).
44. Hallahan DE. Radiation-mediated gene expression in the pathogenesis of the clinical radiation response. Semin. Radiat. Oncol. 6(4), 250-267 (1996).
45. Hallahan DE. Introduction. Semin. Radiat. Oncol. 6(4), 243-244 (1996).
46. Hallahan DE, Virudachalam S. Accumulation of P-selectin in the lumen of irradiated blood vessels. Radiat. Res. 152(1), 6-13 (1999).
47. Staba MJ, Wickham TJ, Kovesdi I, Hallahan DE. Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models. Cancer Gene Ther. 7(1), 13-19 (2000).
48. Edwards E, Geng L, Tan J, Onishko H, Donnelly E, Hallahan DE. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res. 62(16), 4671-4677 (2002).
49. Hallahan D, Geng L, Qu S et al. Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell. 3(1), 63-74 (2003).
50. Hallahan DE, Geng L, Cmelak AJ et al. Targeting drug delivery to radiation-induced neoantigens in tumor microvasculature. J. Control Release 74(1-3), 183-191 (2001).
51. Geng L, Osusky K, Konjeti S, Fu A, Hallahan D. Radiation-guided drug delivery to tumor blood vessels results in improved tumor growth delay. J. Control Release 99(3), 369-381 (2004).
52. Schueneman AJ, Himmelfarb E, Geng L et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 63(14), 4009-4016 (2003).
53. Lu B, Geng L, Musiek A et al. Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium. Int. J. Radiat. Oncol. Biol. Phys. 58(3), 844-850 (2004).
54. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279(5349), 377-380 (1998).
55. Baillie CT, Winslet MC, Bradley NJ. Tumour vasculature - a potential therapeutic target. Br. J. Cancer. 72(2), 257-267 (1995).
56. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79(7), 1157-1164 (1994).
57. Burg MA, Pasqualini R, Arap W, Ruoslahti E, Stallcup WB. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res. 59(12), 2869-2874 (1999).
58. Ellerby HM, Arap W, Ellerby LM et al. Anti-cancer activity of targeted proapoptotic peptides. Nat. Med. 5(9), 1032-1038 (1999).
59. Fox SB, Harris AL. Markets of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. Invest. New Drugs 15(1), 15-28 (1997).
60. Molema G, de Leij LF, Meijer DK. Tumor vakular endothelium: barrier or target in tumor directed drug delivery and immunotherapy. Pharm. Res. 14(1), 2-10 (1997).
61. Rajotte D, Ruoslahti E. Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display. J. Biol. Chem. 274(17), 11593-11598 (1999).
62. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display pcptide libraries. Nature 380(6572), 364-366 (1996).
63. Sergeeva A, Kolonin MG, Molldrem JJ, Pasqualini R, Arap W. Display technologies: application for the discovery of drug and gene delivery agents. Adv. Drug Deliv. Rev. 58(15), 1622-1654 (2006).
64. Han Z, Fu A, Wang H et al. Noninvasive assessment of cancer response to therapy. Nat. Med. 14(3), 343-349 (2008).
65. Landon LA, Deutscher SL. Combinatorial discovery of tumor targeting peptides using phage display. J. Cell Biochem. 90(3), 509-517 (2003).
66. Lee SM, Lee EJ, Hong HY et al. Targeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display. Mol. Cancer Res. 5(1), 11-19 (2007).
67. Newton JR, Kelly KA, Mahmood U, Weissleder R, Deutscher SL. In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. Neoplasia 8(9), 772-780 (2006).
68. Ho IA, Lam PY, Hui KM. Identification and characterization of novel human glioma-specific peptides to potentiate tumor-specific gene delivery. Hum. Gene Ther. 15(8), 719-732 (2004).
69. Spear MA, Breakefield XO, Beltzer J et al. Isolation, characterization, and recovery of small peptide phage display epitopes selected against viable malignant glioma cells. Cancer Gene Ther. 8(7), 506-511 (2001).
70. Zhang J, Spring H, Schwab M. Neuroblastoma tumor cell-binding peptides identified through random peptide phage display. Cancer Lett. 171(2), 153-164 (2001).
71. Ruoslahti E. RGD and other recognition sequences for integrins. Annu. Rev. Cell. Dev. Biol. 12, 697-715 (1996).
72. Smith JW, Cheresh DA. The Arg-Gl-Asp binding domain of the vitronectin receptor. Photoaffinity cross-linking implicates amino acid residues 61-203 of the β subunit. J. Biol. Chem. 263(35), 18726-18731 (1988).
73. 3, expression using (64)Cu-labcled tetrameric RGD peptide. J. Nucl. Med. 46(10), 1707-1718 (2005).
74. Eliceiri BP, Cheresh DA. The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest. 103(9), 1227-1230 (1999).
75. Haubner R. αvβ3-integrin imaging: a new approach to characterise angiogenesis? Eur. J. Nucl. Med. Mol. Imaging 33(Suppl. 1), 54-63 (2006).
76. 3 integrin 'vitronectin receptor'. Int. J. Biochem. Cell Biol. 29(5), 721-725 (1997).
77. 3 integrin antagonists: a new class of tracers for tumor targeting. J. Nucl. Med. 40(6), 1061-1071 (1999).
78. 3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61(5), 1781-1785 (2001).
79. 3 integrin binding peptides in a nude mouse model. Cancer Res. 62(21), 6146-6151 (2002).
80. van Hagen PM, Breeman VA, Bernard HF et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for turnout imaging and radionuclide therapy. Int. J. Cancer 90(4), 186-198 (2000).
81. 3-selective tracer 18F-galacto-RGD in cancer patients. J. Nucl. Med. 46(8), 1333-1341 (2005).
82. 3 antagonists. J. Med. Chem. 37(1), 1-8 (1994).
83. Pierschbacher MD, Ruoslahti E. Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J. Biol. Chem. 262(36), 17294-17298 (1987).
84. 3 selected from random phage display libraries. Biochemistry 34(12), 3948-3955 (1995).
85. 1 integrin from phage display library. J. Biol. Chem. 268(27), 20205-20210 (1993).
86. O'Neil KT, Hoess RH, Jackson SA, Ramachandran NS, Mousa SA, DeGrado WF. Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library. Proteins 14(4), 509-515 (1992).
87. 3-integrin expression. J. Nucl. Med. 45(10), 1776-1783 (2004).
88. Chen X, Park R, Hou Y et al. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur. J. Nucl. Med. Mol. Imaging 31(8), 1081-1089 (2004).
89. 125I-labeled RGD peptide are improved by PEGylation. Nucl. Med. Biol. 31(1), 11-19 (2004).
90. Huamani J, Passarella RJ, Onishko HM et al. Rapid assessment of malignant glioma susceptibility to molecular targeted therapy. Int. J. Radiat. Oncol. Biol. Phys. 69(3), S149-S149 (2007).
91. Passarella RJ, Diaz R, Hallahan DE. Rapid recognition of glioma response to radiation therapy using recombinant peptides. Presented at: 99th Annual Meeting of the American Association for Cancer Research (AACR). San Diego, CA, USA, 12-16 April 2008 (Abstract, 1458).
92. Diaz R, Hariri G, Passarella RJ, Wu H, Fu A, Hallahan DE. Radiation-guided platinum drug delivery using recombinant peptides. Int. J. Radiat. Oncol. Biol. Phys. 72(1), S1 (2008).